Glenmark Therapeutics推出仿制药Pataday Twice Daily Relief，目标市场为$26.4M。 Glenmark Therapeutics launches generic Pataday Twice Daily Relief, targeting $26.4M market.
Glenmark Pharmaceuticals的美国子公司Glenmark Therapeutics Inc.推出了盐酸奥洛他定滴眼液0.1%（OTC），这是Pataday Twice Daily Relief的仿制药，针对年销售额为$26.4M的市场。 Glenmark Therapeutics Inc., a US subsidiary of Glenmark Pharmaceuticals, launched Olopatadine Hydrochloride Ophthalmic Solution 0.1% (OTC), a generic version of Pataday Twice Daily Relief, targeting a market with $26.4M annual sales. 公司的OTC销售和营销负责人Fabio Moreno对此次发布表示兴奋,强调公司致力于满足市场需求并提供高质量的OTC解决方案. Fabio Moreno, Head of OTC Sales & Marketing, expressed excitement about the launch, emphasizing the company's commitment to meeting market needs and providing high-quality OTC solutions.